| Date | Title | Description |
| 05.03.2024 | Elafibranor for Primary biliary cholangitis (PBC) in 7MM: Market Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 | - |
| 26.04.2023 | Startup Showcase: GENFIT – Pioneering Innovative Therapeutic and Diagnostic Solutions | GENFIT is a late-stage biopharmaceutical company based in Loos, Nord-Pas-de-Calais, France, dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. GENFIT’s pion... |
| 28.02.2023 | GENFIT Announces Revenues and Cash Position as of December 31, 2022 | Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022.
/EIN News/ -- Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Eu... |
| 19.09.2022 | Genfit to Acquire Versantis | Genfit (Nasdaq and Euronext: GNFT), a Lille and Paris, France, and Cambridge, MA, USA-based late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, is to acquire Versantis, a Swi... |
| 19.09.2022 | GENFIT acquires Swiss biotech Versantis for up to CHF105 million | |
| 20.12.2021 | On heels of global strategic partnership announced, GENFIT acquires rights to novel asset | Lille, France; Cambridge, MA - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is pleased to announce the strengthening of it... |
| 20.12.2021 | GENFIT - Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership | Paris (France) - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT), have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide... |
| 17.12.2021 | GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership - Form 6-K | GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership - Agreement gives Ipsen global* rights to develop and c... |
| 17.12.2021 | GENFIT : On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset - Form 6-K | On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
· Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and Europe
... |
| 17.12.2021 | Ipsen : Genfit Collaboration – 17 December 2021 | Disclaimer: Intended for international media and investor audiences only
Ipsen and GENFIT enter into exclusive licensing agreement for
elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as
part of a long-term global pa... |
| 17.12.2021 | GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership | GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership Agreement gives Ipsen global* rights to develop and com... |
| 17.12.2021 | On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset | Exclusive rights for a novel early-stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and Europe
Phase 2 clinical program expected to start in 1H 2022
Agreement comes on the heels of today’s othe... |
| 19.10.2021 | GENFIT : Corporate Presentation - October 2021 | Corporate Presentation
October 2021
October 18, 2021
Disclaimer & Forward Looking Statements
IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES... |
| 29.09.2021 | GENFIT : 2021 GENFIT Half Year Business and Financial Report | HALF-YEAR
BUSINESS
AND FINANCIAL
REPORT
AT JUNE 30, 2021
CONTENTS
Half-Year Business and Financial Report at June 30, 2021
Half-Year Condensed Consolidated Financial Statements at June 30, 2021
Statutory Auditors' Limited Review Report on 2... |
| 29.09.2021 | GENFIT : Cash and cash equivalents totaled 104 million as of June 30, 2021 (including 11 million non-dilutive financing obtained in the first half 2021) (Form 6-K) | Cash and cash equivalents totaled €104 million as of June 30, 2021 (including €11 million non-dilutive financing obtained in the first half 2021)
o Net income totaled €9 million for the first half 2021, due to a one-off revenue following th... |
| 29.09.2021 | GENFIT : Reports First Half-Year 2021 Financial Results and Provides Corporate Update | GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update Financial highlights Cash and cash equivalents totaled €104 million as of June 30, 2021 (including €11 million non-dilutive financing obtained in the first ... |
| 30.06.2021 | GENFIT : Extra-financial Performance - 2020 Statement | Extra-financial Performance 2020 Statement
Publication: June 30, 2021
We are a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related... |
| 15.06.2021 | GENFIT
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders' vote but quorum not met on first convening | Quorum of 18.19%on first convening
Combined Shareholders Meeting will be reconvened on June30, 2021 with the sameagenda
Votes cast on the first convening remain valid for the second convening
Shareholder engagement remains critical for the ... |
| 15.06.2021 | GENFIT
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders' vote but quorum not met on first convening (Form 6-K) | GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders' vote but quorum not met on first convening
· Quorum of 18.19% on first convening
· Combined Shareholders Meeting will be re... |
| 02.06.2021 | GENFIT
GENFIT : Shareholders' Letter, June 2021 | SHAREHOLDERS' LETTER
N° 12 - June 2021
June 15, 2021 Combined Shareholders' Meeting:
Support your Company's new strategy
Dear Shareholders,
Following your support during our January 2021 shareholders' meeting, GENFIT has completed its conve... |
| 27.05.2021 | GENFIT
GENFIT : Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 (Form 6-K) | GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
Lille, France; Cambridge, MA; May 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to imp... |
| 18.05.2021 | GENFIT
GENFIT : Articles of Association as of March 2, 2021 | UNOFFICIAL TRANSLATION FOR INFORMATION PURPOSES ONLY
GENFIT SA
Corporation with a Board of Directors and a share capital of € 11,146,000.00 Registered office: Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 LOOS 424 341 907 R.C.S. LILLE Mét... |
| 12.05.2021 | GENFIT
GENFIT : Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents (Form 6-K) | GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents
Lille, France; Cambridge, MA; May 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving t... |
| 01.10.2020 | GENFIT
GENFIT : 2020 GENFIT Half year business and financial report | HALF-YEAR BUSINESS AND FINANCIAL REPORT AT JUNE 30, 2020
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2019
[2]
SUMMARY
Half-year business and financial report as of June 30, 2020
Half-year condensed consolidated financial statements as of June... |
| 12.05.2020 | Genfit’s drug flops in Phase III, joining graveyard of NASH failures | Shares of Genfit fell 72.6% on the Euronext Paris market when it opened Tuesday, from 20.22 euros ($21.98) per share to 5.54 euros ($6.02).
Among 1,070 patients enrolled in the intent-to-treat population, the 717 who received the drug showe... |
| 11.05.2020 | Genfit's NASH drug fails a closely-watched PhIII showdown, adding one more setback to a plagued field | Genfit’s bid to make R&D history with a storybook turnaround came to a crashing halt on Monday as the French biotech acknowledged that its Phase III study of elafibranor failed to distinguish itself from placebo in treat... |
| 25.02.2020 | The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year. | Reuters
Advertisement
There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants.
We identified seven biotechs that have staked their companies - a... |
| 26.11.2019 | Genfit scores seventh positive data safety monitoring board opinion for Phase III NASH trial | Shares of Genfit were up 8.3% on the Euronext Paris exchange and 3.5% on the Nasdaq following the news.
The company plans to announce top-line interim results for the study in the first quarter of next year and will file for Food and Drug A... |
| 24.06.2019 | Genfit goes to China with a deal worth up to $228M for NASH drug | Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to... |
| 16.04.2019 | Gilead, Insitro in $250M machine learning partnership to develop NASH drugs | NASH is a form of fatty liver disease incidental to obesity and Type 2 diabetes. It is on the rise around the world and is expected by many analysts to represent a market that will explode in value over the next few years, but as yet has no... |
| 01.04.2019 | Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics | IFM, which focuses on developing therapies that modulate novel targets in the innate immune system, launched IFM Tre in July 2018, for the purpose of developing drugs in a class known as NLRP3 antagonists.
The lead program in IFM Tre’s port... |
| 27.03.2019 | France's NASH contender Genfit leaps onto Nasdaq with $135M IPO | As it gears up for the late-stage readout of its lead experimental NASH drug, France’s Genfit is vaulting onto the Nasdaq on Wednesday with a $135 million IPO under the symbol $GNFT.
The Lille-based company, which is alread... |
| 27.03.2019 | Genfit makes $135M debut on Nasdaq | The company’s therapeutic focus is on nonalcoholic steatohepatitis, or NASH, and its lead product candidate is the drug elafibranor, currently in a pivotal Phase III clinical trial.
NASH is a form of nonalcoholic fatty liver disease associa... |
| 17.03.2019 | Genfit, developing drugs for NASH, to trade on Nasdaq | In a Securities and Exchange Commission filing, the company said it would sell the shares at $26.33, with the anticipation of raking in $119.2 million and a proposed maximum aggregate offering price of $151.4 million. It had filed a draft r... |
| 15.03.2019 | Genfit readies its $120M IPO; Karyopharm shares boosted after an FDA delay for selinexor | → Weeks after officially unveiling its plan to list on the Nasdaq, Lille-based liver drug developer Genfit on Thursday said it would offer 5,000,000 shares in the offering, but is still determining the price (per ADS) ran... |
| 06.12.2018 | While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients | As a late-stage data showdown from NASH drug developers Gilead $GILD, Intercept $ICPT and France’s Genfit (EuroNext: $GNFT) looms, the Lille-based drug developer on Thursday reported positive phase II data on its drug ela... |
| 28.04.2017 | Three major variables that could derail the dash to NASH | It’s a super-sized epidemic that many experts believe holds blockbuster therapeutic potential. That’s driven dozens of companies to enter the so-called “dash to NASH” in hot pursuit of the first FDA approval.
As could be expected, there are... |
| 24.04.2017 | EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay | Over the weekend some of the prospective players in the NASH field had a chance to roll out new data on their contenders for the field at the annual EASL meeting. We were treated to some intriguing early- and mid-stage data on ... |
| 21.04.2017 | Gilead’s billion-dollar NASH acquisition takes some positive first steps | It’s an early win for a drug Gilead acquired from Nimbus Therapeutics in April 2016. A handful of other preclinical programs were included in the deal, which saw Gilead pay an upfront $400 million. A further $200 million was paid out last N... |
| 08.02.2017 | As hep C revenues decline, investors ask: Who is Gilead? | Sales of its chronic hepatitis C virus (HCV) treatments decreased from over $19 billion in 2015 to almost $15 billion in 2016. Looking ahead to 2017, the company expects between $7.5-$9 billion in revenue from its franchise — significantly ... |
| 11.11.2016 | With $100 million buy, BMS targets “richest opportunity for blockbuster drugs” | It’s all very early stage, said Peter Traber, chief medical officer, president and CEO of Galectin Therapeutics, which has a Phase 2 drug in development for late-stage NASH. But with the immense market potential, Bristol-Myer’s $100 million... |
| 31.03.2016 | Genfit moves liver disease pill into mid-stage, hints at upcoming IPO | Genfit's Dean Hum
The French drugmaker Genfit will start a Phase II study in the coming months for its experimental liver damage drug elafibranor as it also hopes for a lull in the financial headwinds to get its IPO off this year.
The compa... |
| - | Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics | A Swiss drugmaker is the latest to make a big bet on the future market for a liver disease that is rapidly growing worldwide and still has no approved therapies.
On Monday, Novartis and Boston-based private drugmaker IFM Therapeutics said N... |
| - | Genfit, developing drugs for NASH, to trade on Nasdaq | A French company specializing in treatments for a form of fatty liver disease becoming more common around the world due to the rise in obesity plans to start selling its shares on the Nasdaq.
Genfit, based near Lille, said Thursday that it ... |
| - | As hep C revenues decline, investors ask: Who is Gilead? | Despite overdelivering on fourth quarter 2016 earnings, shares of Gilead Sciences dropped six points in overnight trading on Tuesday, on the back of poor 2017 sales estimates.
The investor reaction was summed up in the headline of a Seeking... |
| - | Genfit scores seventh positive data safety monitoring board opinion for Phase III NASH trial | The committee overseeing Genfit’s registration-directed Phase III trial testing its drug in a fatty-liver disease without any approved treatments has recommended that the trial move forward.
The Lille, France-based company said Tuesday that... |
| - | Gilead, Insitro in $250M machine learning partnership to develop NASH drugs | A large biotech company has made a deal with a smaller firm to incorporate a new weapon into its arsenal against nonalcoholic steatohepatitis: machine learning.
Foster City, California-based Gilead Sciences said Tuesday that it had partnere... |
| - | Genfit makes $135M debut on Nasdaq | French drugmaker Genfit suspended trading of its shares on European markets Wednesday as it began selling its shares on the US market.
The company said Wednesday that it would offer 6.65 million shares on the Nasdaq at $20.32 apiece, for a ... |
| - | Gilead’s billion-dollar NASH acquisition takes some positive first steps | While a Phase 2 trial powers on, Gilead Sciences has announced some earlier proof-of-concept data for its investigational acetyl-CoA carboxylase (ACC) inhibitor, GS-0976, in patients with non-alcoholic steatohepatitis (NASH).
The results we... |
| - | With $100 million buy, BMS targets “richest opportunity for blockbuster drugs” | Bristol-Myers Squibb (BMS) has deepened its pipeline for fibrosis drugs with the acquisition of a new class of investigational siRNA molecules from Nitto Denko Corporation.
The worldwide licensing deal, announced Thursday, includes Nitto’s ... |
| - | Three major variables that could derail the dash to NASH | The International Liver Congress in Amsterdam has officially wrapped up, but the energy and excitement around NASH – aka non-alcoholic steatohepatitis – persists.
Characterized by inflammation and scarring of the liver, NASH affects an esti... |
| - | Genfit’s drug flops in Phase III, joining graveyard of NASH failures | One of the two lead drug candidates under development for a form of fatty-liver disease has failed, the company developing it said Monday.
Lille, France-based Genfit said Monday that an interim analysis of the Phase III RESOLVE-IT of elafib... |
